Paradromics founder and CEO represented neurotechnology at the White House Summit on Biotechnology and Biomanufacturing
Paradromics Inc. founder and CEO Matt Angle attended yesterday’s White House Summit on Biotechnology and Biomanufacturing, which outlined initiatives and investments stemming from the bipartisan CHIPS and Science Act. We were honored to be included among the invitees, including representatives from industry, academia, and government, and to help bring attention to the neurotech industry.
We are encouraged by the commitments made at the Summit to continued investment in innovative technologies. Paradromics has a proud legacy of public investment from the Defense Advanced Research Projects Agency (DARPA) Neural Engineering System Design (NESD) and The National Institutes of Health Small Business Innovation Research (SBIR) programs. The former was key to our early R&D efforts and the latter is supporting our first translational studies in humans.
Matt also had the opportunity to voice support for strengthening the Breakthrough Devices Program directly to U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra. This program aims to facilitate bringing innovative medical devices to the patients who need them.
Because neurotechnology sits at the intersection of biology and digital technology, it also sits at intersection of these biotech initiatives and the wider CHIPS Act, which aims to ensure ongoing domestic semiconductor manufacturing capabilities. Going forward, a reliable supply of advanced microelectronics will be crucial to bringing much-needed brain computer interface and neuromedicine treatments to market.